Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 17/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733398 | 0.91 | ACLY (0.43) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30733427 | 0.90 | ACLY (0.42) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26969776 | 0.88 | ACLY (0.41) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25237936 | 0.86 | ACLY (0.41) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25237931 | 0.85 | ACLY (0.41) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30733425 | 0.83 | CYP3A4 (0.43) | ACLYNPY5RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25274228 | 0.81 | NPY5R (0.46) | ACLYNPY5R | |
| SCHEMBL26969744 | 0.80 | HTR6 (0.40) | ACLYNPY5R | |
| SCHEMBL25274911 | 0.80 | NPY5R (0.43) | NPY5R | |
| SCHEMBL26969737 | 0.79 | NPY5R (0.42) | ACLYNPY5RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113698-A | TRPML modulators | 卡斯玛治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022032073-A2 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | ACLY 3265/4885NPY5R 681/4885CYP3A4 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.